不同剂量瑞舒伐他汀治疗高危血脂异常患者的疗效和安全性  

Dose-dependent efficacy and safety of rosuvastatin in dyslipidemia patients at high risk for cardiovascular diseases

作　　者：曹平良[1] 李年娥[1] 孙瑜婧[1] 唐琼珍[1] 刘鹃锋 

机构地区：[1]江西省人民医院干部病房,330006 [2]江西省景德镇市第一人民医院内二科,333000

出　　处：《中国老年保健医学》2011年第3期33-35,共3页Chinese Journal of Geriatric Care

摘　　要：目的评价不同剂量瑞舒伐他汀对血脂异常的高危心血管病患者的疗效和安全性。方法 51例高危心血管病的血脂异常患者均接受瑞舒伐他汀10mg/d治疗,8周后将LDL-C达标的患者随机分为两组:瑞舒伐他汀10mg/d组(A组)19例;瑞舒伐他汀5mg/d组(B组)18例,继续治疗8周。观察4周、8周和16周后各组调脂、LDL-C达标率和不良反应发生率等指标变化。结果 4周后,LDL-C下降27.72,达标率52.94;8周后,LDL-C下降37.52,达标率72.55,HDL-C上升2.89。与A组相比,B组LDL-C有明显上升(2.13±0.35vs2.93±0.36mmol/L,P<0.05),LDL-C达标率明显下降(89.47vs38.89,P<0.01),两组差异有统计学意义。试验中两组均未发现与药物相关的严重不良反应事件。结论瑞舒伐他汀10mg/d可明显快速降低LDL-C和TC,升高HDL-C,并且具有良好的安全性和耐受性,但瑞舒伐他汀5mg/d则不能使高危血脂异常患者LDL-C持续达标。Objective To evaluate the dose-dependent efficacy and safety of rosuvastatin in dyslipidemia patients at high risk for cardiovascular diseases.Methods 51 dyslipidemia patients at high risk for cardiovascular diseases were all administrated rosuvastatin 10mg per day orally.The patients who reached the target level defined by ATP III after 8 weeks were randomly divided into two groups,of which rosuvastatin 10mg per day（group A） in 19 cases and rosuvastatin 5mg per day（group B） in 18 cases.The lipidlowing efficacy and adverse events were compared after another 8 weeks.Results After 4 weeks,LDL-C reduced 27.72,the target LDL-C goal rate 52.94.After 8 weeks,LDL-C reduced 37.52,the target LDL-C goal rate 72.55,meanwhile HDL-C increased 2.89.Compared with group A,LDL-C in group B rose significantly（2.13 ± 0.35 vs 2.93 ± 0.36mmol/L,P 0.05）,but the target LDL-C goal rate decreased significantly（89.47 vs 38.89,P 0.01）.The difference between two groups was statistically significant.It was difficult to sustain the ATP III target level with rosuvastatin 5mg per day.There were no drug-related serious adverse events during the study.Conclusions It is showed that,rosuvastatin 10mg per day,not 5mg per day,significantly and sustainably reduced LDL-C and TC,increasing HDL-C at the same time,both with good safety and tolerance in the high-risk dyslipidemia patients.

关 键 词：瑞舒伐他汀 血脂异常 高危心血管病患者 

分 类 号：R589.2[医药卫生—内分泌]